GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-06-27| R&D

Vaxxas: A Needleless Way to Administer Vaccines With HD-MAP Technology

by GeneOnline
Share To
source: https://www.vaxxas.com/

Vaxxas represents the next generation of vaccines, utilizing an innovative technology called HD-MAP. This technology has the potential to enhance the effectiveness of existing vaccines. By employing microprojections that penetrate the skin and reach the immune cells directly underneath, the vaccine components are able to quickly travel to the lymph nodes. The introduction of this new vaccination technique offers three key advantages: firstly, it eliminates the requirement for refrigeration, secondly, it is highly efficient in terms of dosage, and thirdly, it has the potential for self-administration.

Related article: Valneva’s Breakthrough Chikungunya Single-shot Vaccine: Release Phase 3 Data

Overcoming Vaccine refrigeration and Enabling Self-Administration 

The current need for refrigeration poses significant challenges for many vaccines, as they can lose effectiveness without proper cooling. This becomes particularly problematic when vaccines need to be transported to regions without electricity or where power outages frequently occur. Furthermore, a lack of trained personnel capable of administering vaccines correctly results in the underutilization of certain vaccines. Vaxxas addresses these issues by providing thermal stability for specific vaccines, rendering refrigeration unnecessary. Additionally, its needle-free administration makes self-administration a possibility.

Advancing Clinical Trials and Scaling up Production for Future Availability

Vaxxas is presently undergoing six clinical trials involving different vaccines. It is currently in Phase I of clinical trials for COVID-19 and influenza vaccines. The company has established a new facility to expand the production of HD-MAP vaccines and is actively preparing for the launch of its initial commercial products. Although they are not currently available for purchase, it is anticipated that they will be in the near future.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Saudi Arabia Reveals Grand Ambition to Become a Global Biotech Powerhouse by 2040
2024-01-26
An Interview with AusBiotech CEO Lorraine Chiroiu, Highlighting Innovations and Growth in the Australian Biotech Sector
2023-12-16
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top